171 filings
Page 5 of 9
8-K
7ds v6f2etk
9 Dec 19
Entry into a Material Definitive Agreement
8:15am
8-K
bvwxtcrky2
4 Nov 19
Trevena Reports Third Quarter 2019 Results and Topline Data From Multi-Dose Healthy Volunteer QT Study
7:02am
8-K
5p7oih
6 Sep 19
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:15pm
8-K
ka8xdh2vnb16ptnp9h
7 Aug 19
Trevena Reports Second Quarter 2019 Results
7:02am
8-K
hduil dkq
27 Jun 19
Trevena Appoints Barry Shin as Chief Financial Officer
7:05am
8-K
cm72jos jqq
17 May 19
Submission of Matters to a Vote of Security Holders
9:16am
8-K
5ts7b8zq
10 May 19
Trevena Reports First Quarter 2019 Results
7:03am
8-K
9kwaxdd97 sot
17 Apr 19
Entry into a Material Definitive Agreement
5:04pm
8-K
se3gcq
13 Mar 19
Trevena Reports Fourth Quarter and Full Year 2018 Results
7:03am
8-K
18i2q f9f
7 Mar 19
Other Events
4:02pm
8-K
hy8h631
1 Mar 19
Departure of Directors or Certain Officers
4:01pm
8-K
akvfpllhhgsppbw39
11 Feb 19
Other Events
4:01pm
8-K
h9lshoq4t
1 Feb 19
Entry into a Material Definitive Agreement
9:30am
8-K
4v68ym 9w2
30 Jan 19
Trevena Announces $10 Million Registered Direct Offering of Common Stock
7:13am
8-K
13z9xlchux09rcox
28 Jan 19
Trevena Announces Receipt of Type A Meeting Minutes and Provides Regulatory Update for Oliceridine
7:05am
8-K
vte0x
21 Dec 18
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
8:00am
8-K
ee7stsiw
8 Nov 18
Trevena Reports Third Quarter 2018 Financial Results and Announces Workforce Restructuring
7:06am
8-K
co2j9mp973 k7hj4ei
2 Nov 18
Trevena Receives Complete Response Letter for Oliceridine from FDA
4:01pm
8-K
mb67s269af8ecnyspl
17 Oct 18
Entry into a Material Definitive Agreement
4:26pm
8-K
y0j1qp6dsbrqsza
12 Oct 18
Trevena Announces Oliceridine FDA Advisory Committee Meeting Outcome
7:00am